EXICURE, INC. (XCUR) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US30205M3097

Price
1.06 USD
Market cap
6.94 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

EXICURE, INC. financials

Fiscal year2025
Revenue0.00 USD
Operating income-4.23 m USD
EBIT-5.61 m USD
Net income-4.95 m USD
Diluted EPS – continuing operations-0.79 USD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About EXICURE, INC.

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.